CSIMarket Company Name, Ticker, Suppliers, else..
 
Precision Biosciences Inc  (NASDAQ: DTIL)
 
Price: $7.6400 $-0.14 -1.799%
Day's High: $7.800000190734863 Week Perf: -10.64 %
Day's Low: $ 7.49 30 Day Perf: 9.3 %
Volume (M): 214,809 52 Wk High: $ 9.62
Volume (M$): $ 0 52 Wk Avg: $6.08
Open: $7.75 52 Wk Low: $3.53



 Market Capitalization (Millions $) 188
 Shares Outstanding (Millions) 25
 Employees 68
 Revenues (TTM) (Millions $) 45
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 26
 Capital Exp. (TTM) (Millions $) 0

Business Description


Precision Biosciences Inc. is a biotechnology company founded in 2006 with headquarters in Durham, North Carolina. The company is focused on developing genome editing technologies that enable the precise modification of genes. Precision Biosciences utilizes its proprietary ARCUS Genome Editing technology, which is based on a naturally occurring enzyme called the homing endonuclease I-CreI. This technology allows for modifications in a wide range of cell types, including difficult-to-edit cells such as stem cells.

The company primarily aims to address genetic disorders and improve the development of cell and gene therapies. Precision Biosciences has collaborations with multiple pharmaceutical and biotechnology companies to develop and commercialize therapeutic products based on its genome editing platform. The company's lead product candidate, PBCAR0191, is a CD19-targeted CAR T-cell therapy being developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL).

Precision Biosciences also has a diverse pipeline of other genome editing programs targeting various diseases, including genetic diseases, cancer, and infectious diseases. The company has established partnerships with other companies in the field to leverage its genome editing technology for agricultural applications and sustainable food production.

In summary, Precision Biosciences Inc. is a biotechnology company working on developing precise and versatile genome editing technologies to address genetic disorders, improve cell and gene therapies, and explore other applications in agriculture and food production.


   Company Address: 302 East Pettigrew St. Durham 27701 NC
   Company Phone Number: 314-5512   Stock Exchange / Ticker: NASDAQ DTIL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -5.92%    
BDTX   -2.55%    
IMCR   -0.79%    
IPSC   -3.3%    
KRYS        5.16% 
RGNX        17.94% 
• View Complete Report
   



Business Update

Precision BioSciences Pioneering the Path to Hepatitis B Cure with Cutting-Edge Gene Editing,

Published Fri, Sep 12 2025 2:45 PM UTC

Gene Editing Advances: Precision BioSciences Unveils Promising HBV Trial Results and Strategic Insights In an era marked by dynamic scientific advancements, Precision BioSciences, Inc., a frontrunner in the realm of gene editing, has once again underscored its commitment to tackling diseases with profound unmet medical needs. Leveraging the innovative ARCUS platform, the Dur...
Business Update

Navigating Challenges, Driving Innovation Precision BioSciences Strategic Endeavors in Gene Editing,

Published Thu, May 8 2025 12:09 PM UTC

Precision BioSciences: Navigating Losses Amid Promising Developments in Gene Editing Precision BioSciences, Inc. is set to announce its first quarter 2025 financial results on May 15. As the company navigates the complexities of its financial landscape, marked by a higher operating loss of $25 million compared to $21.28 million in the previous quarter, it continues to stren...
Business Update

Precision BioSciences Engages Investors Amid Market Underperformance,

Published Thu, Nov 21 2024 1:34 PM UTC

Precision BioSciences to Engage in Investor Conferences Amidst Market Challenges Precision BioSciences, a prominent player in the field of genome editing and therapeutic development, is set to participate in a series of investor conferences throughout November. This engagement is part of the company s ongoing effort to communicate its corporate strategies, innovation pipelin...
Business Update

Precision BioSciences Advances PBGENE-HBV to Clinical Trials for Chronic Hepatitis B Therapy.

Published Fri, Nov 15 2024 12:56 PM UTC

DURHAM, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing enterprise, has revealed compelling preclinical data today that supports the advancement of its innovative therapeutic candidate, PBGENE-HBV, towards clinical development. The company plans to initiate its first-in-human clinical trial, dubbed ELIMINATE-B, aimed at treating patients suf...
Business Update

Precision BioSciences Striving for Clinical Success Amidst Financial Challenges,

Published Tue, Nov 5 2024 8:21 AM UTC

Precision BioSciences: Navigating Challenges and Achievements in the Gene Editing Landscape Precision BioSciences, Inc. a clinical-stage gene editing company based in Durham, North Carolina, continues to make strides in the biotechnology sector, notably through its proprietary ARCUS platform. The company recently released its financial results for the third quarter of 2024, ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.18
Price to Sales (Expected) -
Price to Book 2.47
PEG (TTM) -

Financial Strength Current
Quick Ratio 13.05
Working Capital Ratio 14.02
Leverage Ratio (MRQ) 0.89
Total Debt to Equity 0.29
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.15 $
Revenues (TTM) 1.83 $
Cash Flow (TTM) 1.06 $
Cash 4.11 $
Book Value 3.09 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 662,838
Net Income per Employee (TTM) -641,176
Receivable Turnover Ratio (TTM) 45.03
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.36

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -83.73 %
Net Margin (MRQ) -170.15 %
Net Cash Flow Margin (MRQ) -104.32 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Precision Biosciences Inc's Segments
Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.